How has this study helped patients and researchers?
Patients with advanced ovarian cancer who responded to previous chemotherapy took
part in this study. Researchers concluded that niraparib reduced the risk of cancer
growth or return or death compared with placebo. The side effects reported in this
study were as expected.
Are there plans for further studies?
Other studies of niraparib in patients with ovarian cancer have been conducted and
some are ongoing or planned.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events. When the study is complete, final results will be
available in the scientific summaries.
Organisation and Website Study Number
European Medicines Agency
2015-000952-111
(www.clinicaltrialsregister.eu)
United States National Institutes of Health (NIH)
NCT026550162
(www.clinicaltrials.gov)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000952-11
2https://clinicaltrials.gov/ct2/show/study/NCT02655016